BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Bio Reports

Promontory Therapeutics Exceeds Interim Efficacy Bar In Thymoma Study With PT 112

Three of the first 10 patients with thymoma evaluated by RECIST have partial responses. Findings exceed protocol requirement of two re...

December 24, 2025 | News

Japan Approves Incyte’s Zynyz As First Line Treatment For Advanced Anal Canal Cancer

Incyte Biosciences Japan G.K. announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination w...

December 23, 2025 | News

Merck Secures World First Regulatory Approval For Pimicotinib In Rare Joint Tumour TGCT In China

First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER study In MANEUVER, pimicotinib significantl...

December 23, 2025 | News

Atom Therapeutics Secures FDA Approval To Advance Phase II Trial Of ABP 745 In Atherosclerosis

Atom Therapeutics, a clinical stage biotechnology company developing best-in-class treatments for inflammatory and metabolic diseases, today announced FDA ...

December 18, 2025 | News

AusperBio Reports 30% Functional Cure Rate With AHB 137 In Chronic Hepatitis B

AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (together AusperBio), a clinical-stage biotechnology company developing oli...

December 16, 2025 | Report

APAC Biopharma Review 2025: Innovation, Investment, and Influence on the Global Stage

APAC Biopharma in Review: What Truly Moved the Needle This Year Asia-Pacific (APAC) has cemented its status as a pivotal biopharmaceutical hub in 2025, ma...

December 15, 2025 | Report

Top 25 Biotech Innovations Redefining Health And Planet In 2025

Biotechnology in 2025 is no longer confined to the laboratory bench. It is curing inherited blood disorders, changing how we prevent HIV, reimagining Alzhe...

December 10, 2025 | Report | By BioPharma APAC Wrap Up 2025

How Health Systems Are Reshaping Drug Adoption, Partner Models, and Market Access in 2026

Health systems have become more consolidated. Some are acting as both providers and payers, and therefore have more influence as gatekeepers of market acce...

December 10, 2025 | Report

Aurigene Oncology Reports Strong Early Phase One Results For AUR112 In Relapsed And Refractory Lymphomas

Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology, announced initial clinical results...

December 04, 2025 | News

Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs

An international survey, spanning Australia, France, Japan, Poland and the UK, has found that many employees experiencing fertility challenges lack support...

November 27, 2025 | Report

The New AI Gold Rush: Western Pharma’s Billion-Dollar Bet on Chinese Biotech

Global pharmaceutical companies are racing to tap China’s new AI-powered biotech platforms to discover drugs faster and cheaper. In 2025, major Weste...

November 27, 2025 | Analysis

Kelun Biotech Reports Strong Phase Three Success for Sac TMT and Keytruda in First Line Lung Cancer

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced that the Independent Data Monitoring Committee (IDMC) concluded t...

November 25, 2025 | News

Tsingke Biotech Showcases Breakthrough Speed in Protein and Antibody Development at PEGS Europe 2025

At PEGS Europe 2025, one of the industry's premier gatherings for innovation in protein and antibody engineering, Tsingke Biotech highlighted its latest ac...

November 20, 2025 | News

Mabwell Secures NMPA Approval to Begin Phase II Trial of First-in-Class Anti-IL-11 Antibody for Pathological Scarring

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that its novel anti‑IL‑11 monoclonal antibody...

November 12, 2025 | News

Stay Connected